Phaseline

Targets › IL12

IL12: drug programs, companies and trials

16 programs from 13 companies in 21 trials: 19 Phase 1, 1 Phase 2, 1 Phase 3; Oncology, Infectious disease; next expected readout Dec 2026.

Open in Phaseline: the race on IL12, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
ImunonIMNN-001 (GEN-1)
IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer
IL12Phase 3Epithelial Ovarian Cancer; Ovarian CancerJun 2027
Geneos TherapeuticsINO-9012
plasmid encoded interleukin-12 (IL-12) vaccine adjuvant
IL12Phase 2HCCNov 2028
National Cancer Institute (NCI)Edodekin alfa
Recombinant interleukin-12
IL12Phase 1Metastatic Malignant Solid Neoplasm; Metastatic Head and Neck Squamous Cell CarcinomaDec 2026
Suzhou Abogen BiosciencesABO2011
mRNA encoding human single-chain IL-12 protein
IL12Phase 1Solid Tumor, AdultDec 2026
Kangabio AUSTRALIAKGX101
Heterodimeric IL-12 prodrug with masked N-terminus and ADCC-impaired IgG1 Fc fusion
IL12, IL12RB1, IL12RB2Phase 1Advanced or Metastatic Solid TumorsJan 2027
National Cancer Institute (NCI)INO-9012
DNA plasmid encoding interleukin-12 (IL-12)
IL12Phase 1Chronic HepatitisMar 2027
Washington University School of MedicineINO-9012
Plasmid encoded IL-12
IL12Phase 1GlioblastomaMar 2027
Strand TherapeuticsSTX-001
Self-replicating RNA encoding IL-12 delivered via lipid nanoparticle (LNP) for intratumora
IL12Phase 1Advanced Solid TumorMay 2027
M.D. Anderson Cancer CenterattIL2-T cells
T-cell membrane-anchored tumor-targeted IL-12
IL12Phase 1Soft Tissue SarcomaSep 2027
VLP TherapeuticsVRP-encapsulated saRNA encoding IL-12 (VLPONC-01)
Viral replicon particle (saRNA) expressing IL-12
IL12Phase 1Head and Neck Cancers- Squamous CellDec 2027
Inovio PharmaceuticalsINO-9012
DNA plasmid encoding human interleukin-12 (IL-12)
IL12Phase 1GlioblastomaDec 2027
enGeneEG-70 (detalimogene voraplasmid)
Viral vector-delivered IL-12 gene therapy for intravesical bladder instillation
IL12Phase 1Superficial Bladder CancerApr 2028
TrogenixTGX-007
AAV-mediated dual-payload gene therapy delivering HSV-tk and IL-12 for tumor cell killing
HSV-TK, IL12Phase 1Glioblastoma (GBM)Mar 2030
Strand TherapeuticsSTX-003
LNP-formulated self-replicating mRNA encoding human IL-12 with miRNA target sites for cont
IL12Phase 1Advanced Solid TumorJul 2030
M.D. Anderson Cancer CenterT Cell Membrane-Anchored Tumor-Targeted IL12-Modified TIL Cell Therapy (attIL12-
T cell membrane-anchored tumor-targeted IL-12 expressing tumor infiltrating lymphocyte (TI
IL12Phase 1Metastatic Soft-tissue SarcomaDec 2030
Sonnet BioTherapeuticsSON-1010
Recombinant IL-12 fused to albumin-binding domain (FHAB) for albumin hitchhiking and tumor
IL12Phase 1Advanced Solid Tumor–

Conditions

Advanced Solid Tumor (3) HCC (2) Epithelial Ovarian Cancer (2) Advanced or Metastatic Solid Tumors (2) Glioblastoma (2) Solid Tumor, Adult (1) Ovarian Cancer (1) Soft Tissue Sarcoma (1) Head and Neck Cancers- Squamous Cell (1) Superficial Bladder Cancer (1) Metastatic Malignant Solid Neoplasm (1) Metastatic Head and Neck Squamous Cell Carcinoma (1)

Modalities

mixed (8), protein or peptide (5), other (2), small molecule (1)

Companies

M.D. Anderson Cancer Center (2) Strand Therapeutics (2) National Cancer Institute (NCI) (2) Geneos Therapeutics (1) Suzhou Abogen Biosciences (1) Imunon (1) VLP Therapeutics (1) Sonnet BioTherapeutics (1) Kangabio AUSTRALIA (1) enGene (1) Inovio Pharmaceuticals (1) Washington University School of Medicine (1) Trogenix (1)

Related targets

IL12RB1 (1) IL12RB2 (1) HSV-TK (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.